---
title: "Bio Essence 2025 10-K: Revenue $1.90M, EPS $0.02"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280839238.md"
description: "Bio Essence reported a significant revenue increase to $1.898 million in 2025, up from $0.324 million in 2024, driven by a strategic shift to outsourced OEM manufacturing services. The company achieved a net income of $896,197 and earnings per share of $0.02, marking a return to profitability. Key highlights include a 486% revenue growth, improved gross profit of $1.428 million, and a controlled cost structure. The company has ceased in-house product sales and now focuses solely on OEM services following the sale of its previous subsidiaries."
datetime: "2026-03-27T19:45:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280839238.md)
  - [en](https://longbridge.com/en/news/280839238.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280839238.md)
generator: "portal-rs"
---

# Bio Essence 2025 10-K: Revenue $1.90M, EPS $0.02

Bio Essence reported a sharp revenue rebound to $1.898 million in 2025, driven by increased OEM service volume, with basic and diluted net income per share of $0.02 reflecting a return to profitability. The improvement in top-line sales and higher gross margins on OEM services contributed to operating income of $900,011 and net income of $896,197 for the year. These results follow a strategic shift away from in‑house product sales toward outsourced OEM manufacturing services.

**Financial Highlights**

-   **Total revenues**: $1.898 million (up from $0.324 million in 2024)
-   **Gross profit**: $1.428 million (up from $0.217 million in 2024)
-   **Income (loss) from operations**: $900,011 (compared to $(459,438) in 2024)
-   **Net income (loss)**: $896,197 (compared to $(1,308,796) in 2024)
-   **Basic and diluted net income per share**: $0.02 (compared to $(0.03) per share in 2024)

**Business Highlights**

-   **Revenue growth driver**: Revenue surged approximately 486% to $1.90M in 2025, primarily from large OEM service orders from three new major clients.
-   **Channel shift**: The company executed a strategic pivot from product sales to providing OEM manufacturing services; product sales declined to nil in 2025.
-   **Operational outsourcing**: Following the sale of BEP and BEH, the company now outsources manufacturing and OEM operations rather than conducting in‑house production.
-   **Cost and margin momentum**: As OEM services scaled, gross profit improved materially while the company maintained a controlled cost structure.
-   **R&D subsidiary status**: McBE, an R&D/prescription drug focused subsidiary, was formed and later dissolved; the company remains concentrated on supplement OEM services.

Original SEC Filing: Bio Essence Corp \[ BIOE \] - 10-K - Mar. 27, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [MBIO.US](https://longbridge.com/en/quote/MBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [GBIO.US](https://longbridge.com/en/quote/GBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**